Evidence map›Paper›PMID 37952030›Full record

Trial reportScientific reports2023

Development of a potency assay for CD34

Anne Aries, Christine Vignon, Céline Zanetti, Aurélien Goubaud, Arthur Cormier, Anne Diederichs, Rachid Lahlil, Philippe Hénon, Ibon Garitaonandia

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. CD34Histology and histopathology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anne Aries *Institut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.
Christine Vignon *CellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Céline ZanettiInstitut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.
Aurélien GoubaudCellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Arthur CormierCellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Anne DiederichsCellProthera SAS, 12 Rue du Parc, Mulhouse, France.
Rachid LahlilInstitut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.
Philippe HénonInstitut de Recherche en Hématologie et Transplantation, Hôpital du Hasenrain, 87 Avenue d'Altkirch, Mulhouse, France.
Ibon GaritaonandiaCellProthera SAS, 12 Rue du Parc, Mulhouse, France. igaritaonandia@cellprothera.com.
Institut de Recherche en Hématologie et Transplantation · FRHôpital du Hasenrain · FRInnothera (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have previously shown that intracardiac delivery of autologous CD34

Indexed as

Endothelial Progenitor CellsMicroRNAsMyocardial InfarctionAntigens, CD34HumansNeovascularization, PhysiologicVascular Endothelial Growth Factor AAntigens, CD34MicroRNAsVascular Endothelial Growth Factor A

Identifiers

PMID37952030
PMCPMC10640600
OpenAlexW4388586360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.